The Pro Medicus Limited (ASX: PME) share price is up almost 5% and has hit an all-time high today on the back of pleasing news.

Pro Medicus is a Melbourne-based software owner and developer, licensing products to large US hospitals and Australian radiology clinics. The company has offices in Richmond, Victoria, Berlin, Germany and in the United States.

The Pro Medicus Share Price Just Hit An All-Time High

Pro Medicus announced that it has signed a 7-year contract with Duke Health, which is the largest health system in the state of North Carolina, it’s also one of the most respected health providers in North America according to Pro Medicus.

The contract is based on a transaction licensing model and will see the Visage 7 technology implemented across all of Duke’s radiology departments and integrated into Duke’s electronic health records.

This is a sizeable deal because it will span three hospitals and “dozens” of additional locations across Duke Health including the 957-academic medical center, Duke University Hospital. The planning to process the implementation is expected to start soon and the first sites are expected to go live in the first quarter of FY20.

Pro Medicus CEO Dr Sam Hupert said:

This not only helps consolidate our strong position in this highly competitive market, it enables us to leverage our development and commercialisation efforts across an increasing base of academic, research orientated clients which we feel provides us with a strategic advantage particularly in rapidly evolving fields such as AI and machine learning.”

Is Pro Medicus A Great ASX Growth Share?

This deal adds to others previously announced including a $3 million deal in Germany and a different $27 million US deal.

Pro Medicus is undoubtedly a high quality business with a growing market share and improving profit margins, it has most of the things you could want from an investment, I wish I could have invested at the start of the decade!

However, no business is a buy at a super-expensive price. I’m not sure what the right entry price would be, but investors seem perhaps too excited by Pro Medicus right now.

The growth shares in the free report below could be better ideas to own for the long term at today’s price.

After searching through a market with over 2,000 shares, our lead expert investment analyst has narrowed it down to just 2 of his favourite small-cap pocket rocket share ideas in a FREE report to Rask Media readers.

Over the past five years, these two shares have gone from being 'tiny caps' to being serious contenders for the ASX 200. Investment in these types of companies have the potential to change lives.

Access the free report by clicking here now or enter your email below! Absolutely no credit card or payment details required.



Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).

At the time of publishing, Jaz does not have a financial interest in any of the companies mentioned.